| 1 |
34942306 | AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway. | 2022 Mar 1 |
2 |
| 2 |
35399501 | AZD5153, a Bivalent BRD4 Inhibitor, Suppresses Hepatocarcinogenesis by Altering BRD4 Chromosomal Landscape and Modulating the Transcriptome of HCC Cells. | 2022 |
4 |
| 3 |
35480096 | MUS81 Inhibition Enhances the Anticancer Efficacy of Talazoparib by Impairing ATR/CHK1 Signaling Pathway in Gastric Cancer. | 2022 |
1 |
| 4 |
33838899 | Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification. | 2021 Jul |
4 |
| 5 |
34160250 | SARS-CoV-2 Spike Protein Induces Paracrine Senescence and Leukocyte Adhesion in Endothelial Cells. | 2021 Aug 10 |
1 |
| 6 |
32184777 | BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages. | 2020 |
3 |
| 7 |
29931583 | Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. | 2019 Apr |
4 |
| 8 |
31142662 | The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. | 2019 Aug |
2 |
| 9 |
31523195 | BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor. | 2019 |
4 |
| 10 |
29596834 | AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo. | 2018 May 15 |
6 |
| 11 |
29636547 | BRD4 facilitates replication stress-induced DNA damage response. | 2018 Jul |
1 |
| 12 |
30036377 | BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. | 2018 |
2 |
| 13 |
30304769 | A Novel t(8;14)(q24;q11) Rearranged Human Cell Line as a Model for Mechanistic and Drug Discovery Studies of NOTCH1-Independent Human T-Cell Leukemia. | 2018 Oct 9 |
2 |
| 14 |
28073847 | Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors. | 2017 Feb 15 |
1 |
| 15 |
28378926 | Translational Modeling of Drug-Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor. | 2017 Jun |
2 |
| 16 |
27573426 | AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. | 2016 Nov |
4 |